11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
24 Jul
 
Først så tager skattevæsenet  halvdelen af din indkomst.  - Så tager banken 200 kr i kurtage (Udenla..
38
27 Jul
 
  Indledning Over sommeren har jeg læst adskillige bøger om aktier og investering, som har givet mig..
30
27 Jul
 
Tese Toneangivende vestlige lande er på vej i fuld fart i retning mod ekspansiv finanspolitik. Dette..
28
24 Jul
 
Til gengæld er operation ved sygdom gratis....Hvis du overlever ventetiden.   Til gengæld kan du som..
28
28 Jul
 
Det er nu to døgn + ca. 3 timer siden du sidst oprettede en tråd, stillede det samme spørgsmål vedr...
16
27 Jul
VELO
Og flyt så - for en tid - fokus hen på "ejerne" af Veloxis Pharmaceuticals. Især den ene - NOVO A/S ..
15
28 Jul
GEN
På mange måder ligger Genmab lige nu (kort sigt) i et "alting kan ske" område. Overordnet set ligger..
14
24 Jul
 
ER DET IKKE FEDT AT BO I ET LAND SOM DANMARK, uanset hvor meget I brokker jer over det ene eller and..
14
28 Jul
FING-B
Når man ikke tænker i analyser: Deværre tror jeg ikke, at kursen for FPC bliver stabil, så længe der..
13
24 Jul
 
Jeg kender et par stykker som er flyttet til USA (og også et par stykker i Tyskland). Deres rådighed..
13

Form 8.3 - Anheuser-Busch InBev SA/NV

29/07/2016 15:25:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

PayPoint plc : Director/PDMR Shareholding

29/07/2016 13:19:43
29 July 2016 PayPoint plc ("the Company") As a result of transactions on 29 July 2016 by the PayPoint plc Share Incentive Plan (a HM Revenue & Customs..

Statement re Amendment to Official List, Share Consolidation and Total Voting Rights

29/07/2016 10:00:21
Intermediate Capital Group plc (the "Company") 29 July 2016 Amendment to Official List, Share Consolidation and Total Voting Rights Further to the ap..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Groupe BPCE: 2016 stress test confirms Groupe BPCE's financial strength
2
ADVA Optical Networking SE: Publication pursuant to §26a WpHG (the German Securities Trading Act) with the aim of pan-European distribution
3
Publicis Groupe Statement

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
31 July 2016 02:37:13
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160728.2 - EUROWEB1 - 2016-07-31 03:37:13 - 2016-07-31 02:37:13 - 1000 - Website: OKAY